Advertisement
Document › Details
Basilea Pharmaceutica Ltd.. (3/1/18). "Press Release: Basilea Names Adesh Kaul as New Member of its Management Committee". Basel.
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as Chief Corporate Development Officer effective March 01, 2018. He will continue to be responsible for strategic planning, business development & licensing, investor relations and public relations.
Mr. Kaul has served as Basilea's Head of Corporate Development and as a member of Basilea's Extended Management Committee since March 2016. Before joining Basilea, he held various positions at Polyphor Ltd., including CFO and Head Corporate Development. Prior to this, he served as Basilea's Head Business Development, Licensing & Investor Relations and Head Public Relations & Corporate Communications. In addition, he was a senior financial analyst at Neue Zürcher Bank covering Swiss pharmaceutical and biotech stocks and held various positions in general management and sales & marketing at bioinformatics company Genedata AG. Mr. Kaul holds Master degrees both in biochemistry and economics from the University of Basel, and received an Executive MBA from HSG St. Gallen.
Ronald Scott, Chief Executive Officer, commented: "I am pleased to further strengthen our Management Committee by the addition of Adesh Kaul as Chief Corporate Development Officer. He has been leading our partnering activities, which has resulted in us successfully establishing development and commercialization partnerships for our hospital anti-infectives portfolio with leading pharmaceutical companies around the world. Under his leadership, our commercialized drugs are now partnered in over 100 countries. Adesh's expertise is particularly valuable for managing Basilea's strategic planning and business development activities as we continue to focus on strengthening our R&D portfolio."
About Basilea
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
+41 61 606 1102
media_relations@basilea.com
investor_relations@basilea.com
Record changed: 2023-06-05 |
Advertisement
More documents for Basilea (Group)
- [1] Basilea Pharmaceutica Ltd.. (4/4/24). "Press Release: Basilea Announces US FDA Approval of Antibiotic Zevtara (ceftobiprole medocaril) for Three Indications". Allschwil....
- [2] Nodus Oncology Ltd.. (9/6/22). "Press Release: Nodus Oncology Announces Acquisition of Basilea Pharmaceutica’s PARG Inhibitor Programme". Edinburgh....
- [3] Coulter Partners. (7/4/18). "Press Release: Coulter Partners Secures Chief Technology Officer for Basilea Pharmaceutica International Ltd."....
- [4] Basilea Pharmaceutica Ltd.. (2/27/18). "Press Release: Basilea Reports Significantly Improved Financial Results in 2017". Basel....
- [5] Basilea Pharmaceutica Ltd.. (2/23/18). "Press Release: Basilea Reports Clinical Phase 3 Study Start with Antibiotic Ceftobiprole in Skin Infections under BARDA Contract". Basel....
- [6] Basilea Pharmaceutica Ltd.. (2/21/18). "Press Release: Basilea's CEO Ronald Scott Will Retire. Chief Commercial Officer David Veitch Named as Successor – Changes in the Board of Directors". Basel....
- [7] Basilea Pharmaceutica Ltd.. (1/10/18). "Press Release: Basilea Announces Completion of the License Agreement Extension with Pfizer for Antifungal Cresemba for China and Asia Pacific". Basel....
- [8] Basilea Pharmaceutica Ltd.. (12/1/17). "Press Release: Basilea Extends Existing License Agreement with Pfizer for Antifungal Cresemba (isavuconazole) to China and Asia Pacific". Basel....
- [9] Basilea Pharmaceutica Ltd.. (9/28/17). "Press Release: Basilea Announces License Agreement for Antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd.". Basel....
- [10] Basilea Pharmaceutica Ltd.. (8/10/17). "Press Release: Basilea Reports Improved Financial Results in Half-year 2017 Driven by Growing Product Sales, Significant Progress on Partnering and Development Programs". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top